earnings
confidence high
sentiment positive
materiality 0.75
Apogee reports Q1 net loss $55.3M; positive APG808 Phase 1b data with 53% FeNO suppression
Apogee Therapeutics, Inc.
2025-Q1 EPS reported
-$0.95
- Q1 net loss $55.3M vs $32.1M YoY; cash $681.4M supports runway into Q1 2028.
- Positive interim Phase 1b APG808 results: FeNO suppression 53% max, sustained 50% at 12 weeks; well tolerated.
- Phase 2 APEX trial of APG777 advancing; interim Part A 16-week data expected mid-2025.
- First patient dosed in Phase 1b APG777 asthma trial; readout expected 1H 2026.
- APG279 (APG777+APG990) head-to-head vs DUPIXENT on track to initiate in 2025; readout 2H 2026.